Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and others in the Cambridge-London life sciences corridor, and wider local and international ecosystems.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault

BURLINGAME, Calif., May 20, 2026 /PRNewswire/ -- Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.

J A Kemp webinar: Emotional Perception, G1/19 and software inventions in the UK and EPO

This webinar will discuss the impact of the Enlarged Board Simulation decision G1/19 and the UK Supreme Court Judgment in Emotional Perception on practice at the EPO and the UK IPO, particularly looking at appeal decisions. Although generally endorsing prior case law, G1/19 has prompted a greater level of concentration on ensuring that the requirements of patentability, especially technical character, are met over the whole scope of the claims. Emotional Perception directs UK examiners and courts to follow EPO practice more closely.

Coulter Partners places Dr. Ferenc Tracik as Chief Medical Officer of Neumirna Therapeutics

LONDON, UK, and COPENHAGEN, Denmark – May 14, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Neumirna Therapeutics (“Neumirna”) and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer (CMO). 

Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 18 May 2026: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.

OutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-based Target Discovery

 

  • Funding to identify novel targets for ALS treatment using OutSee’s ‘genomics first’ target discovery platform, Nomaly
  • Provides access to world’s largest and most comprehensive ALS patient dataset
  • Part of £7.5M global challenge prize to leverage innovations in AI-based discovery

 

LSX Congress USA

LSX CONGRESS USA brings together biotech leaders, pharma BD teams and active investors from across North America and beyond, creating a focused environment for strategic conversations, investment discussions and partnership development.

For life science companies, the Congress offers a valuable opportunity to build visibility with the US and global market, connect with investors, and engage with pharma BD teams exploring new innovation, licensing and partnership opportunities.

Subscribe to